What is Roivant?
Founded in 2014 and headquartered in London, Roivant Sciences operates as a tech-enabled healthcare enterprise dedicated to the acquisition and development of late-stage drug candidates. The company distinguishes itself through a 'Vant' model, where individual subsidiaries are established to focus on specific therapeutic areas or technologies. This approach allows for specialized management and focused resource allocation, effectively de-risking the development process while accelerating the delivery of innovative treatments to patients globally. Roivant's market position is defined by its agility in identifying undervalued assets and its commitment to integrating advanced data analytics into the clinical trial process.
How much funding has Roivant raised?
Roivant has raised a total of $1.4B across 3 funding rounds:
Private Equity
$100M
Private Equity
$1.1B
Private Equity
$200M
Private Equity (2014): $100M with participation from Dexcel Pharma and QVT Financial
Private Equity (2017): $1.1B led by Dexcel Pharma and Softbank
Private Equity (2018): $200M supported by RTW Investments and NovaQuest Capital Management
Key Investors in Roivant
RTW Investments
RTW is a life sciences investment and innovation firm that focuses on biotech and medtech innovation throughout the entire lifecycle, from company creation to public companies.
Softbank
SoftBank Group Corp. is a global technology holding company driving innovation across telecommunications, internet services, artificial intelligence, and clean energy technologies.
Dexcel Pharma
Dexcel Pharma is Israel’s largest privately owned pharmaceutical company, developing and manufacturing branded prescription drugs, generics, and OTC products.
What's next for Roivant?
With the recent influx of capital, Roivant is well-positioned to advance its pipeline of late-stage assets and expand its technological infrastructure. The strategic focus will likely shift toward optimizing clinical trial efficiency and scaling its digital health initiatives, which are critical for maintaining a competitive edge in the rapidly evolving biotech sector. As the company matures, the emphasis will remain on achieving regulatory milestones and potentially exploring new therapeutic modalities. The continued support from its diverse investor base provides the necessary runway to sustain long-term growth and solidify its influence in the global pharmaceutical market.
See full Roivant company page
